bizjournalarticle-vertical.jpg
The three deals that Mediware has completed since November 2007 have helped it broaden its product line and deepen its core business...Read More

2009 Investor Meeting

The 2009 annual investor meeting is scheduled for December 3 in New York City.  Click below for additional information

  • Review the proxy
  • This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Business Overview
Mediware develops, markets, licenses, implements and supports clinical management information solutions. The Company's solutions are primarily designed to create an automated "closed loop" clinical system for the management of medication and blood in hospitals, blood centers, and long-term care and behavioral health facilities.

Mediware's products have been designed to address a significant problem in the healthcare industry. Traditional healthcare environments include collections of disparate information systems and manual processes used by clinicians throughout the care process. The result is reduced efficiency and increased safety risks due to the potential for human error and delayed access to patient information and records as patients progress through the continuum of care. When dealing with blood or medications, errors and delays can often result in tragic consequences.

The Company's products address these clinical issues with "suites" of applications that provide clinicians one data environment for all information relating to the prescribing, preparation, and administration of drug or blood therapies. The Company's two primary product lines manage each step of the therapeutic processes, from the ordering to the fulfillment, administration and documentation, providing care providers a "closed loop" process environment for blood and medication therapies, which the Company believes differentiates it from the industry's catalog and "best of breed" vendors.

The statements contained in this website which are not historical facts are forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company's control, with respect to market acceptance of new technologies and products and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.

 

Financial News

Earnings Call Reports

Please login to view reports

Client Success

Integration between blood bank and EMR drives efficiencies.


Overview: University of Toledo Medical Center implements HCLL in combination with McKesson’s Horizon Lab™ to manage transfusions for Level I Trauma Center.

Read more...